

# Martin W Häußler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717200/publications.pdf>

Version: 2024-02-01

121  
papers

2,826  
citations

159585

30  
h-index

214800

47  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3532  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of inter-observer delineation variability on radiomics stability in different tumor sites. <i>Acta Oncologica</i> , 2018, 57, 1070-1074.	1.8	152
2	Clinical applications of SPECT/CT in imaging the extremities. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 50-58.	6.4	141
3	Contrast-Enhanced PET/MR Imaging Versus Contrast-Enhanced PET/CT in Head and Neck Cancer: How Much MR Information Is Needed?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 551-558.	5.0	123
4	The EANM practice guidelines for parathyroid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2801-2822.	6.4	116
5	Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain <sup>18</sup> F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1927-1932.	5.0	102
6	Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks – Initial results. <i>Lung Cancer</i> , 2018, 126, 170-173.	2.0	90
7	Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction. <i>Journal of Nuclear Medicine</i> , 2016, 57, 215-220.	5.0	80
8	Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations. <i>Radiology</i> , 2014, 273, 859-869.	7.3	78
9	Clinical performance of <sup>68</sup> Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 20-30.	6.4	72
10	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 4414-4425.	7.0	70
11	PET/MR in Cancers of the Head and Neck. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 248-265.	4.6	69
12	PET/MRI and PET/CT in follow-up of head and neck cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1066-75.	6.4	68
13	TNM Staging of Non-Small Cell Lung Cancer: Comparison of PET/MR and PET/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 21-26.	5.0	65
14	Reduction of <sup>18</sup> F-FDG Dose in Clinical PET/MR Imaging by Using Silicon Photomultiplier Detectors. <i>Radiology</i> , 2018, 286, 249-259.	7.3	59
15	CT radiomics and PET radiomics: ready for clinical implementation?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 355-370.	0.7	58
16	Impact of a Bayesian penalized likelihood reconstruction algorithm on image quality in novel digital PET/CT: clinical implications for the assessment of lung tumors. <i>EJNMMI Physics</i> , 2018, 5, 27.	2.7	51
17	Imaging in primary hyperparathyroidism: focus on the evidence-based diagnostic performance of different methods. <i>Minerva Endocrinology</i> , 2018, 43, 133-143.	1.1	47
18	<sup>18</sup> F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. <i>Journal of Nuclear Medicine</i> , 2016, 57, 849-854.	5.0	44

#	ARTICLE	IF	CITATIONS
19	PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. <i>Clinical Imaging</i> , 2017, 42, 232-239.	1.5	43
20	<sup>68</sup> Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 147-159.	6.4	43
21	The potential of machine learning to predict postoperative pancreatic fistula based on preoperative, non-contrast-enhanced CT: A proof-of-principle study. <i>Surgery</i> , 2020, 167, 448-454.	1.9	43
22	Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. <i>BMC Cancer</i> , 2015, 15, 1002.	2.6	42
23	[ <sup>18</sup> F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact. <i>European Radiology</i> , 2022, 32, 508-516.	4.5	41
24	Artificial intelligence for detecting small FDG-positive lung nodules in digital PET/CT: impact of image reconstructions on diagnostic performance. <i>European Radiology</i> , 2020, 30, 2031-2040.	4.5	39
25	Maximum Standardized Uptake Value (SUV <sub>max</sub> ) of Primary Tumor Predicts Occult Neck Metastasis in Oral Cancer. <i>Scientific Reports</i> , 2018, 8, 11817.	3.3	38
26	PET/MR Outperforms PET/CT in Suspected Occult Tumors. <i>Clinical Nuclear Medicine</i> , 2017, 42, e88-e95.	1.3	37
27	Metal artifact reduction in patients with dental implants using multispectral three-dimensional data acquisition for hybrid PET/MRI. <i>EJNMMI Physics</i> , 2014, 1, 102.	2.7	36
28	Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. <i>Head and Neck</i> , 2017, 39, 1550-1558.	2.0	35
29	[ <sup>18</sup> F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. <i>Molecular Imaging and Biology</i> , 2018, 20, 857-867.	2.6	33
30	Comparison of Contrast-Enhanced CT and [ <sup>18</sup> F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer. <i>Molecular Imaging and Biology</i> , 2017, 19, 795-803.	2.6	32
31	PET/MR in Head and Neck Cancer – An Update. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 26-38.	4.6	30
32	Dose Optimization in TOF-PET/MR Compared to TOF-PET/CT. <i>PLoS ONE</i> , 2015, 10, e0128842.	2.5	30
33	Multi-Atlas-Based Attenuation Correction for Brain <sup>18</sup> F-FDG PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas and CT-Based Attenuation Correction. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1258-1264.	5.0	29
34	Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 685-690.	1.1	29
35	Comparing diagnostic accuracy of <sup>18</sup> F-FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected vascular graft infections. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1359-1368.	6.4	28
36	Diagnostic Accuracy of PET/CT and Contrast Enhanced CT in Patients With Suspected Infected Aortic Aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> , 2020, 59, 972-981.	1.5	26

#	ARTICLE	IF	CITATIONS
37	Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup> F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	5.0	25
38	Imaging Non-Specific Wrist Pain: Interobserver Agreement and Diagnostic Accuracy of SPECT/CT, MRI, CT, Bone Scan and Plain Radiographs. <i>PLoS ONE</i> , 2013, 8, e85359.	2.5	24
39	Oral manifestation of Langerhans cell histiocytosis: a case report. <i>BMC Oral Health</i> , 2018, 18, 106.	2.3	24
40	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. <i>Diagnostics</i> , 2020, 10, 1083.	2.6	23
41	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	3.8	23
42	Interchangeability of radiomic features between [ <sup>18</sup> F]â€‹ <sup>18</sup> F-FDG PET/CT and [ <sup>18</sup> F]â€‹ <sup>18</sup> F-FDG PET/MR. <i>Medical Physics</i> , 2019, 46, 1677-1685.	3.0	22
43	Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer. <i>Scientific Reports</i> , 2019, 9, 8972.	3.3	21
44	Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1223-1233.	6.4	20
45	Impact of different image reconstructions on PET quantification in non-small cell lung cancer: a comparison of adenocarcinoma and squamous cell carcinoma. <i>British Journal of Radiology</i> , 2019, 92, 20180792.	2.2	20
46	Cluster-based segmentation of dual-echo ultra-short echo time images for PET/MR bone localization. <i>EJNMMI Physics</i> , 2014, 1, 7.	2.7	18
47	<sup>18</sup> F-FET PET for Diagnosis of Pseudoprogression of Brain Metastases in Patients With Nonâ€‹Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, 113-117.	1.3	17
48	Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study. <i>European Radiology</i> , 2022, 32, 1823-1832.	4.5	17
49	Effect of Time-of-Flight Information on PET/MR Reconstruction Artifacts: Comparison of Free-breathing versus Breath-hold MR-based Attenuation Correction. <i>Radiology</i> , 2017, 282, 229-235.	7.3	16
50	Impact of PET data driven respiratory motion correction and BSREM reconstruction of <sup>68</sup> Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS). <i>Scientific Reports</i> , 2021, 11, 2273.	3.3	15
51	Feasibility of <sup>18</sup> F-FDG Dose Reductions in Breast Cancer PET/MRI. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1817-1822.	5.0	14
52	CT-perfusion in peripheral arterial disease â€‹Correlation with angiographic and hemodynamic parameters. <i>PLoS ONE</i> , 2019, 14, e0223066.	2.5	14
53	Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma â€‹Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. <i>Frontiers in Oncology</i> , 2021, 11, 664304.	2.8	14
54	Pulmonary nodule detection in oncological patients â€‹Value of respiratory-triggered, periodically rotated overlapping parallel T2-weighted imaging evaluated with PET/CT-MR. <i>European Journal of Radiology</i> , 2018, 98, 165-170.	2.6	13

#	ARTICLE	IF	CITATIONS
55	Current concepts in advanced sinonasal mucosal melanoma: a single institution experience. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2259-2265.	1.6	13
56	Value of SUVmax for the Prediction of Bone Invasion in Oral Squamous Cell Carcinoma. <i>Biology</i> , 2020, 9, 23.	2.8	13
57	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT. <i>European Radiology</i> , 2021, 31, 8011-8020.	4.5	12
58	PET/CT helps to determine treatment duration in patients with resected as well as inoperable alveolar echinococcosis. <i>Parasitology International</i> , 2021, 83, 102356.	1.3	12
59	Visualization of Parathyroid Hyperplasia Using 18F-Fluorocholine PET/MR in a Patient With Secondary Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2016, 41, e159-e161.	1.3	11
60	Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease—Preliminary Experience From a Retrospective Analysis. <i>Clinical Nuclear Medicine</i> , 2018, 43, e385-e391.	1.3	11
61	Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 1670.	2.8	11
62	CT perfusion in peripheral arterial disease—hemodynamic differences before and after revascularisation. <i>European Radiology</i> , 2021, 31, 5507-5513.	4.5	11
63	Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging. <i>EJNMMI Research</i> , 2021, 11, 79.	2.5	11
64	Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. <i>Swiss Medical Weekly</i> , 2015, 145, w14116.	1.6	11
65	Expanding the clinicopathological spectrum of <i>TGFBR3</i> rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 94-104.	2.8	11
66	Diagnostic accuracy of computed tomography and magnetic resonance imaging compared to surgical exploration for anterior skull base and medial orbital wall infiltration in advanced sinonasal tumors. <i>Head and Neck</i> , 2020, 42, 2002-2012.	2.0	10
67	NEMA NU 2—2018 performance evaluation of a new generation 30-cm axial field-of-view Discovery MI PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3023-3032.	6.4	10
68	Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma. <i>Cancers</i> , 2019, 11, 1329.	3.7	9
69	PET/CT in therapy control of infective native aortic aneurysms. <i>Scientific Reports</i> , 2021, 11, 5065.	3.3	9
70	Clinical evaluation of data-driven respiratory gating for PET/CT in an oncological cohort of 149 patients: impact on image quality and patient management. <i>British Journal of Radiology</i> , 2021, 94, 20201350.	2.2	9
71	Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI—What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?. <i>European Journal of Radiology</i> , 2022, 146, 110044.	2.6	9
72	Histopathological Features of Parathyroid Adenoma and 18F-Choline Uptake in PET/MR of Primary Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2022, 47, 101-107.	1.3	9

#	ARTICLE	IF	CITATIONS
73	The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1167-1173.	5.0	8
74	Value of 18F-FET PET in adult brainstem glioma. <i>Clinical Imaging</i> , 2018, 51, 68-75.	1.5	8
75	Value of PET/MRI for assessing tumor resectability in NSCLC—“intra-individual comparison with PET/CT. <i>British Journal of Radiology</i> , 2018, , 20180379.	2.2	8
76	Use of MRI and FDG-PET/CT to predict fixation of advanced hypopharyngeal squamous cell carcinoma to prevertebral space. <i>Head and Neck</i> , 2019, 41, 503-510.	2.0	8
77	True absopal effect in a patient with metastatic non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 194.	2.7	8
78	Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT. <i>EJNMMI Research</i> , 2014, 4, 6.	2.5	7
79	Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. <i>BMC Medical Imaging</i> , 2015, 15, 60.	2.7	7
80	Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 163-170.	2.0	7
81	18F-NaF-PET/CT in patients with primary hyperparathyroidism and brown tumors. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 299-309.	2.7	7
82	Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination. <i>PLoS ONE</i> , 2020, 15, e0230618.	2.5	7
83	Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021, 13, 2725.	3.7	7
84	The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer’s diseases—A simulation study combining multi-center data and ADNI-data. <i>PLoS ONE</i> , 2020, 15, e0233886.	2.5	6
85	Hybrid positron emission tomography imaging for initial staging of sinonasal tumors: Total lesion glycolysis as prognosticator of treatment response. <i>Head and Neck</i> , 2021, 43, 238-246.	2.0	6
86	FDG-PET/MRI in head and neck squamous cell carcinoma: Impact on pretherapeutic N classification, detection of distant metastases, and second primary tumors. <i>Head and Neck</i> , 2021, 43, 2058-2068.	2.0	6
87	Impact of unknown incidental findings in PET/CT examinations of patients with proven or suspected vascular graft or endograft infections. <i>Scientific Reports</i> , 2021, 11, 13747.	3.3	6
88	Whole-body hybrid positron emission tomography imaging yields clinically relevant information in the staging and restaging of sinonasal tumors. <i>Head and Neck</i> , 2021, 43, 3572-3585.	2.0	6
89	[18F]-sodium fluoride PET/MR for painful lumbar facet joint degeneration—a randomized controlled clinical trial. <i>Spine Journal</i> , 2022, 22, 769-775.	1.3	6
90	The Effect of Defective PET Detectors in Clinical Simultaneous [18F]FDG Time-of-Flight PET/MR Imaging. <i>Molecular Imaging and Biology</i> , 2017, 19, 626-635.	2.6	5

#	ARTICLE	IF	CITATIONS
91	Impact of PET/CT among patients with suspected mycotic aortic aneurysms. <i>PLoS ONE</i> , 2021, 16, e0258702.	2.5	5
92	An essential practice summary of the new EANM guidelines for parathyroid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	5
93	BSREM for Brain Metastasis Detection with 18F-FDG-PET/CT in Lung Cancer Patients. <i>Journal of Digital Imaging</i> , 2022, 35, 581-593.	2.9	5
94	Tumor cell viability in salvage neck dissections: Poor prognosis predicted by high postradiation nodal SUV max , p16 negativity, and low nodal shrinkage. <i>Head and Neck</i> , 2020, 42, 660-669.	2.0	4
95	Predictive value of sumax changes between two sequential post-therapeutic FDG-pet in head and neck squamous cell carcinomas. <i>Scientific Reports</i> , 2020, 10, 16689.	3.3	4
96	Clinical evaluation of PET image quality as a function of acquisition time in a new TOF-PET/MR compared to TOF-PET/CT - initial results. <i>EJNMMI Physics</i> , 2015, 2, A76.	2.7	3
97	Whole-body parametric [18F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2047-2048.	6.4	3
98	SUVmax for predicting regional control in oropharyngeal cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3167-3177.	1.6	3
99	Integrated CT-perfusion shows no meaningful correlation with PSA and presurgical Gleason score in patients with early prostate cancer. <i>Clinical Imaging</i> , 2014, 38, 850-857.	1.5	2
100	FDG-PET/CT: novel method for viability assessment of livers perfused ex vivo. <i>Nuclear Medicine Communications</i> , 2021, 42, 826-832.	1.1	2
101	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 830627.	2.8	2
102	Impact of Bayesian penalized likelihood reconstruction on quantitative and qualitative aspects for pulmonary nodule detection in digital 2-[18F]FDG-PET/CT. <i>Scientific Reports</i> , 2022, 12, 8308.	3.3	2
103	32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii5-ii6.	0.7	1
104	A pilot study on lung cancer detection based on regional metabolic activity distribution in digital low-dose 18F-FDG PET. <i>British Journal of Radiology</i> , 2021, 94, 20200244.	2.2	1
105	Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9575-9575.	1.6	1
106	Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach. <i>Turkish Journal of Urology</i> , 2017, 43, 152-157.	1.3	1
107	Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, , .	0.7	1
108	Frequency and intensity of [ <sup>18</sup> F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET. <i>BJR Open</i> , 2022, 4, .	0.6	1

#	ARTICLE	IF	CITATIONS
109	FDG-PET/CT for oral focus assessment in head and neck cancer patients. <i>Clinical Oral Investigations</i> , 2022, 26, 4407-4418.	3.0	1
110	Value of FDG-PET/MR in Oral Focus Assessment in Head and Neck Cancer Patients – A Feasibility Study. <i>Frontiers in Medicine</i> , 2022, 9, 809323.	2.6	1
111	Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT. <i>Frontiers in Medicine</i> , 2022, 9, 796085.	2.6	1
112	Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series. <i>Head and Neck Pathology</i> , 2022, , .	2.6	1
113	Prognostic value of O-(2-[ <sup>18</sup> F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma. <i>Acta Oncologica</i> , 2020, 59, 1357-1364.	1.8	0
114	Nutrient Challenge Testing Is Not Equivalent to Scintigraphy – Lactulose Hydrogen Breath Testing in Diagnosing Small Intestinal Bacterial Overgrowth. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 514-520.	2.4	0
115	Primary cardiac lymphoma. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 816-816.	1.2	0
116	The role of 99mTc-antigranulocyte SPECT/CT in community-acquired diabetic foot osteomyelitis: A clinical experience. <i>Current Diabetes Reviews</i> , 2021, 17, .	1.3	0
117	COVID-19 and Aspiration Pneumonia: Similar Pulmonary Findings with Different Diagnoses – a Pitfall in [18F]FDG PET/CT. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 2322-2325.	0.6	0
118	Title is missing!. , 2020, 15, e0233886.		0
119	Title is missing!. , 2020, 15, e0233886.		0
120	Title is missing!. , 2020, 15, e0233886.		0
121	Title is missing!. , 2020, 15, e0233886.		0